| Identification | Back Directory | [Name]
Capmatinib hydrochloride | [CAS]
1865733-40-9 | [Synonyms]
Capmatinib hydrochloride
Capmatinib hydrochloride Hydrate | [Molecular Formula]
C23H17FN6O.2HCl.H2O | [MOL File]
1865733-40-9.mol | [Molecular Weight]
466.9 |
| Hazard Information | Back Directory | [Description]
Capmatinib dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Good efficacy in the treatment of non-small cell lung cancer (NSCLC) caused by MET 14 exon skipping mutations. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase[1-3].
| [Origin]
Capmatinib was first reported in 2011 by Liu et al., who showed that in both in vivo and in vitro mice studies using human cell lines, capmatinib had a 10,000-fold selectivity for c-met over a large panel of human kinase. They showed that capmatinib can block the c-MET phosphorylation and activation of downstream targets, including HGF. They further showed that activated c-met upregulates cancer-promoting EGFR and HER-3 pathways. Baltschukat et al. further investigated capmatinib in NSCLC[4].
| [Mechanism of action]
Tabrecta (capmatinib) is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in a protein with a missing regulatory domain that reduces its negative regulation, leading to increased downstream MET signaling. | [Toxicity evaluation]
Effects During Pregnancy and Lactation No information is available on the clinical use of capmatinib during breastfeeding. Because capmatinib is 96% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during capmatinib therapy and for 1 week after the last dose.
| [References]
[1] HSUROBERT NagasakaMisako BenjaminDavid J. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.[J]. Cancers, 2023. DOI:10.3390/cancers15143561.
[2] LIUXIANGDONG. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.[J]. Clinical Cancer Research, 2011. DOI:10.1158/1078-0432.CCR-11-1157.
[3] BALTSCHUKATSABRINA. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.[J]. Clinical Cancer Research, 2019. DOI:10.1158/1078-0432.CCR-18-2814. |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList927327/0.htm |
|